Amendia’s Chairman of the Board of Directors, Dr. Scott Bruder, tapped to speak at prestigious Harvard Business School summit
Amendia, Inc., a leading provider of innovative medical devices and regenerative implants for spinal surgery, is pleased to announce that its Chairman of the Board of Directors, Scott Bruder, MD, PhD, will be a featured speaker at the prestigious Harvard Stem Cell Institute and Harvard Business School summit: The Business of Regenerative Medicine | How to Build a Company conference.
Dr. Bruder is an adjunct Professor of Biomedical Engineering at Case Western Reserve University, and former Industry Member of the FDA Advisory Committee on Cellular, Tissue and Gene Therapies. He is also an advisor to corporations and investors, particularly in the areas of bench-to-bedside product development, innovation and portfolio management, and clinical and regulatory affairs strategy.
Dr. Bruder will join a panel of industry leaders discussing the business of regenerative medicine, including views from the biopharmaceutical, device, manufacturing, tissue bank, regulatory and investment sectors.
The focus of Dr. Bruder’s first presentation will be on trends in cell therapies and regenerative biomaterials. He will outline aspects of the decision-making process around bringing biologic products such as recombinant proteins and cellular allografts in spine, orthopaedics and sports medicine, as well as amniotic tissue derived products to market, for companies like Amendia and others.
On Day Two of the summit, Dr. Bruder will be part of an expert review panel, providing guidance and feedback to a number of development stage firms with tissue repair products, instruments and tools designed for the regenerative medicine industry.
The conference is the 9th program in the Business of Regenerative Medicine series hosted by Harvard Stem Cell Institute and the Harvard School of Business. It is organized by Harvard Stem Cell Institute, Case Western Reserve University, Centre for Commercialization of Regenerative Medicine (Toronto), and the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech. The conference will be held Monday, July 11 to Wednesday, July 13, 2016 at the Harvard School of Business.
This two-and-half day course will focus on the critical issues associated with conceptualizing, developing, and building a company in the field of regenerative medicine. The course is intended for business executives, investors and analysts, technology transfer and development personnel, senior and junior scientists, managers in the government, non-profit and for-profit sectors.
Speakers are leaders in science and industry with a depth and breadth of expertise in bringing regenerative biologics from laboratory to business development.
Headquartered in a state-of-the-art manufacturing facility in Marietta, GA, Amendia, Inc., is a leading designer, developer, manufacturer and marketer of a full-line of medical devices used in spinal surgical procedures, including regenerative biologic products ranging from biocompatible allograft chips and cubes made from cancellous and/or cortical bone, to particulates that provide optimal latticework for osteoconductivity, and cellular allografts containing both marrow-derived cells and bone matrix for bone remodeling and new bone formation.
About The Business of Regenerative Medicine: How to Build a Company
The Business of Regenerative Medicine: How to Build a Company is for individuals in business, academia, and industry interested in conceptualizing, developing, and building a company in the field of regenerative medicine. Boston's Mayor Martin J. Walsh will kick off the event, followed by panel discussions and lectures on translational medicine and entrepreneurship from local biopharma leaders, start-up CEOs, venture capital investors and professors. Speakers include MIT's Robert Langer, GE Venture's Sue Siegel, and the UK-based Cell and Gene Therapy Catapult's Keith Thompson.
“How to Build a Company” is the 9th program in a series organized and managed collaboratively by HSCI, Case Western Reserve University, Centre for Commercialization of Regenerative Medicine (Toronto), and the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech.
About The Harvard Stem Cell Institute:
A leader in the field since 2005, The Harvard Stem Cell Institute is focused on bringing stem cell-derived and based treatments to patients as quickly as possible. To accomplish this, we bring together more than 1,000 scientists in the schools and affiliated hospitals of Harvard, fund novel research, and implement new collaborative academic and industrial models. hsci.harvard.edu
Nikki Coleman, VP-Marketing & Education